Craig Mull - Cipher Pharmaceuticals Interim Chairman
| CPH Stock | CAD 14.40 0.16 1.12% |
Chairman
Mr. Craig J. Mull is Chairman of the Board of the Company. Mr. Mull has extensive experience in the Canadian healthcare industry, including holding the position of COO with CML HealthCare where he was responsible for the daytoday operations. During his tenure at CML, Mr. Mull was part of a small executive team that grew the company from a market cap of 100 million to over 1.2 billion. Mr. Mull also played an integral role in planning and structuring Cipher initial public offering as it was spun out of CML. since 2019.
| Tenure | 5 years |
| Address | 5750 Explorer Drive, Mississauga, ON, Canada, L4W 0A9 |
| Phone | 905 602 5840 |
| Web | https://www.cipherpharma.com |
Cipher Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0506 % which means that it generated a profit of $0.0506 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1798 %, meaning that it generated $0.1798 on every $100 dollars invested by stockholders. Cipher Pharmaceuticals' management efficiency ratios could be used to measure how well Cipher Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 27th of November 2024, Return On Tangible Assets is likely to grow to 0.31. Also, Return On Capital Employed is likely to grow to 0.15. At this time, Cipher Pharmaceuticals' Debt To Assets are very stable compared to the past year. As of the 27th of November 2024, Return On Assets is likely to grow to 0.25, while Total Assets are likely to drop about 46.4 M.Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0506 |
Cipher Pharmaceuticals Leadership Team
Elected by the shareholders, the Cipher Pharmaceuticals' board of directors comprises two types of representatives: Cipher Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cipher. The board's role is to monitor Cipher Pharmaceuticals' management team and ensure that shareholders' interests are well served. Cipher Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cipher Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hamed Ghanei, Chief Officer | ||
| Bryan Jacobs, Chief Officer | ||
| Craig Mull, Interim Chairman | ||
| Emilio Presti, Director Marketing | ||
| Diane Gajewczyk, Vice Affairs | ||
| Chuoru Li, Co Controller | ||
| David Miller, Director Fin |
Cipher Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cipher Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0506 | ||||
| Profit Margin | 0.60 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 423.92 M | ||||
| Shares Outstanding | 25.59 M | ||||
| Shares Owned By Insiders | 42.00 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 127.32 K | ||||
| Price To Earning | 21.55 X |
Pair Trading with Cipher Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Cipher Stock
| 0.78 | AMZN | Amazon CDR | PairCorr |
| 0.67 | BNS | Bank of Nova Scotia Earnings Call This Week | PairCorr |
| 0.65 | BMO | Bank of Montreal | PairCorr |
| 0.45 | RY | Royal Bank Earnings Call This Week | PairCorr |
| 0.41 | TD-PFI | Toronto Dominion Bank | PairCorr |
The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.
The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.